<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Strict//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-strict.dtd"><html xml:lang="en" lang="en" xmlns="http://www.w3.org/1999/xhtml"><head><meta http-equiv="Content-Type" content="text/html; charset=utf-8" /><meta name="ROBOTS" content="NOARCHIVE" /><meta name="googlebot" content="nosnippet" /><meta name="Document-Type" content="interaction" /><meta name="keywords" content="" /><title>Protein Kinase Inhibitors: British National Formulary</title><link type="text/css" rel="stylesheet" href="../../theme/theme.css" /><link type="text/css" rel="stylesheet" href="../../theme/print.css" media="print" /><link type="text/css" rel="stylesheet" href="59/style.css" /><link type="image/x-icon" rel="shortcut icon" href="favicon.ico" /><link rel="stylesheet" type="text/css" href="style/screen.css" media="screen" /><link rel="stylesheet" type="text/css" href="style/print.css" media="print" /><link rel="contents" type="text/html" href="index.htm" /><link rel="help" type="text/html" href="http://www.medicinescomplete.com/mc/help_page.htm" /><link rel="start" type="text/html" href="index.htm" title="British National Formulary" /><link rel="copyright" type="text/html" href="PHP0-publication-information.htm" title="Copyright information" /><link rel="bookmark" title="Skip Navigation" href="bnf_int1087-protein-kinase-inhibitors.htm#pB" /><script type="text/javascript" src="https://ajax.googleapis.com/ajax/libs/jquery/1.7.0/jquery.min.js"></script><script type="text/javascript" src="../../scripts/jquery/jquery.tooltip.min.js"></script><script type="text/javascript" src="../../scripts/jquery/jquery.cookie.js"></script><script type="text/javascript" src="../../scripts/jquery/jquery.autosuggest.js"></script><script type="text/javascript" src="../../scripts/scripts.js"></script><style type="text/css">
  .contentsbox { position: fixed; z-index:1001;}
  .contentsbox_wrap {overflow:hidden;width:20px;height:130px; position:absolute;left:0;top:0;}
</style><!--[if lte IE 7]>
          <style type="text/css">
          .contentsbox {
          position: absolute;
          left: expression( ( 15 + ( ignoreMe2 = document.documentElement.scrollLeft ? document.documentElement.scrollLeft : document.body.scrollLeft ) ) + 'px' );
          top: expression( ( 250 + ( ignoreMe = document.documentElement.scrollTop ? document.documentElement.scrollTop : document.body.scrollTop) ) + 'px' );
          }
          .threecol_col3 {
          font-family: arial
          }
          .threecol_col3 a {
          font-family: verdana,helvetica,sans-serif
          }
          .threecol_col1 {
          font-family: arial
          }
          .threecol_col1 a {
          font-family: verdana,helvetica,sans-serif
          }
          div#pE {
          font-family: arial
          }
          div#pE a {
          font-family: verdana,helvetica,sans-serif
          }
          div#pK {
          font-family: arial
          }
          div#pK a {
          font-family: verdana,helvetica,sans-serif
          }
          </style>
          <![endif]--></head><body><?highlighter off?><div id="pU"><a id="pD" accesskey="s" rel="bookmark" href="bnf_int1087-protein-kinase-inhibitors.htm#pB" title="Skip Navigation">Skip Navigation</a><img src="../../images/mylogo.png" alt="BNF.org Free Access" id="pI" /><ul id="pZ"><li><a href="http://www.medicinescomplete.com/mc/account.htm">You are signed in as a member of <b>BNF.org Free Access</b></a></li><li> | <a href="http://www.medicinescomplete.com/mc/login.htm">Sign in different user</a></li><li> | <a href="http://www.medicinescomplete.com/mc/logout.htm">Sign out</a></li></ul><a href="http://www.medicinescomplete.com/mc/" title="Go to the MedicinesComplete home page"><img src="../../images/mc.png" alt="MedicinesComplete" /></a><ul id="pM"><li><a href="http://www.medicinescomplete.com/mc/" class="selected" accesskey="1" title="Home: access key 1"><strong><span>Home</span></strong></a></li><li><a href="http://www.medicinescomplete.com/mc/marketing/current/"><strong><span>Welcome</span></strong></a></li><li><a href="http://www.medicinescomplete.com/mc/feedback.htm?pub=bnf&amp;uri=bnf_int1087-protein-kinase-inhibitors.htm" accesskey="9" title="Feedback: access key 9"><strong><span>Feedback</span></strong></a></li><li><a href="http://www.medicinescomplete.com/mc/help.htm" accesskey="6" title="Help button: access key 6"><strong><span>Help</span></strong></a></li></ul></div><div id="pA"><div id="pY">British National Formulary</div><div id="pG">Printed from: Joint Formulary Committee.  <i>British National Formulary</i>. [online] London: BMJ Group and Pharmaceutical Press.. &lt; http://www.medicinescomplete.com/ &gt; [Accessed on 07 Oct 2012 (GMT)].</div><div id="pQ"><form id="searchForm" method="get" action="http://www.medicinescomplete.com/mc/bnf/current/search.htm"><fieldset><legend>Details</legend><label for="q">Search for</label><div id="qd"><div><input accesskey="4" type="text" id="q" name="q" /><input class="button" id="searchButton" type="submit" value="Search" name="searchButton" title="Search full text" /></div></div></fieldset></form><script type="text/javascript">$(document).ready(function(){$("#q").autoSuggest('http://www.medicinescomplete.com/mc/bnf/current/search/suggest.xml', {control: "#searchButton"});});</script></div></div><div id="pH"><div id="pN"><div id="pT"><span class="cA"><a href="http://www.medicinescomplete.com/mc/">Home</a></span> &gt; <a href="index.htm">BNF September 2012</a> &gt; <a href="PHP8848-interactions.htm">Appendix 1 Interactions</a> &gt; <a href="PHP8852-list-of-drug-interactions.htm">List of drug interactions</a> &gt; <a href="bnf_int500-cytotoxics.htm">Cytotoxics</a></div><div id="pP"><div class="threecol_col1">◄ <a accesskey="[" href="bnf_int1103-trabectedin.htm" title="Previous: Trabectedin">Previous page</a></div><div class="threecol_col2"> </div><div class="threecol_col3"><a accesskey="]" href="bnf_int1229-vemurafenib.htm" title="Next: Vemurafenib">Next page</a> ►</div></div></div></div><div id="p1"><div id="pB"><h1>Protein Kinase Inhibitors</h1><?highlighter on?><div id="pC" class="jN"><p><strong>Protein Kinase Inhibitors</strong> has no specific interaction information.</p><p><strong>Protein Kinase Inhibitors</strong> belongs to <strong>Cytotoxics</strong> and will have the following interaction information:</p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cAG" /><col width="40%" class="cAF" /><col width="30%" class="cAH" /></colgroup><tbody><tr><td><a href="bnf_int364-clozapine.htm">Clozapine</a></td><td class="cAI"><p><span>avoid concomitant use of </span> <span>cytotoxics</span> <span>with</span> <span>clozapine</span> <span>(increased risk of agranulocytosis)</span>  </p></td><td><div class="cG"><p><strong>Note:</strong> Avoid concomitant use of clozapine with drugs that have a substantial potential for causing agranulocytosis</p></div></td></tr></tbody></table><p><strong>Vemurafenib</strong> belongs to <strong>Protein Kinase Inhibitors</strong> and has the following interaction information:</p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cAG" /><col width="40%" class="cAF" /><col width="30%" class="cAH" /></colgroup><tbody><tr><td><a href="bnf_int277-carbamazepine.htm">Carbamazepine</a></td><td><p><span>manufacturer of </span> <span>vemurafenib</span> <span>advises avoid concomitant use with</span> <span>carbamazepine</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int636-oestrogens.htm">Oestrogens</a></td><td class="cAI"><p><span>manufacturer of </span> <span>vemurafenib</span> <span>advises contraceptive effect of</span> <span>oestrogens</span> <span>possibly reduced</span>  </p></td><td><div class="cG"><p><strong>Note:</strong> Interactions of combined oral contraceptives may also apply to combined contraceptive patches and vaginal rings, see <a title="COCs interactions (target-block)" href="PHP4869-combined-hormonal-contraceptives.htm#PHP4875">section 7.3.1</a></p></div></td></tr><tr><td><a href="bnf_int284-phenytoin.htm">Phenytoin</a></td><td><p><span>manufacturer of </span> <span>vemurafenib</span> <span>advises avoid concomitant use with</span> <span>phenytoin</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int664-progestogens.htm">Progestogens</a></td><td class="cAI"><p><span>manufacturer of </span> <span>vemurafenib</span> <span>advises contraceptive effect of</span> <span>progestogens</span> <span>possibly reduced</span>  </p></td><td><div class="cG"><p><strong>Note:</strong> Interactions of combined oral contraceptives may also apply to combined contraceptive patches and vaginal rings, see <a href="PHP4869-combined-hormonal-contraceptives.htm#PHP4875">section 7.3.1</a>. For further information on interactions of oral progestogen-only contraceptives, see also <a href="PHP4944-oral-progestogen-only-contraceptives.htm#PHP4945">section 7.3.2.1</a>; parenteral progestogen-only contraceptives, see also <a href="PHP4960-parenteral-progestogen-only-contraceptives.htm#PHP4965">section 7.3.2.2</a>; the intra-uterine progestogen-only device, see also <a href="PHP4973-intra-uterine-progestogen-only-device.htm#PHP4974">section 7.3.2.3</a>; hormonal emergency contraception, see also <a href="PHP5019-hormonal-methods.htm#PHP5024">section 7.3.5</a></p></div></td></tr><tr><td><a href="bnf_int200-rifabutin.htm">Rifabutin</a></td><td><p><span>manufacturer of </span> <span>vemurafenib</span> <span>advises avoid concomitant use with</span> <span>rifabutin</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int201-rifampicin.htm">Rifampicin</a></td><td><p><span>manufacturer of </span> <span>vemurafenib</span> <span>advises avoid concomitant use with</span> <span>rifampicin</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int905-st-johns-wort.htm">St John's Wort</a></td><td><p><span>manufacturer of </span> <span>vemurafenib</span> <span>advises avoid concomitant use with</span> <span>St John's wort</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int222-warfarin.htm">Warfarin</a></td><td class="cAI"><p><span></span> <span>vemurafenib</span> <span>possibly enhances anticoagulant effect of</span> <span>warfarin</span> <span></span>  </p></td><td></td></tr></tbody></table><p><strong>Vandetanib</strong> belongs to <strong>Protein Kinase Inhibitors</strong> and has the following interaction information:</p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cAG" /><col width="40%" class="cAF" /><col width="30%" class="cAH" /></colgroup><tbody><tr><td><a href="bnf_int118-amiodarone.htm">Amiodarone</a></td><td class="cAI"><p><span>possible increased risk of ventricular arrhythmias when </span> <span>vandetanib</span> <span>given with</span> <span>amiodarone</span> <span>—avoid concomitant use</span>  </p></td><td><div class="cG"><p><strong>Note:</strong> Amiodarone has a long half-life; there is a potential for drug interactions to occur for several weeks (or even months) after treatment with it has been stopped</p></div></td></tr><tr><td><a href="bnf_int809-amisulpride.htm">Amisulpride</a></td><td class="cAI"><p><span>possible increased risk of ventricular arrhythmias when </span> <span>vandetanib</span> <span>given with</span> <span>amisulpride</span> <span>—avoid concomitant use</span>  </p></td><td></td></tr><tr><td><a href="bnf_int1168-arsenic-trioxide.htm">Arsenic Trioxide</a></td><td class="cAI"><p><span>possible increased risk of ventricular arrhythmias when </span> <span>vandetanib</span> <span>given with</span> <span>arsenic trioxide</span> <span>—avoid concomitant use</span>  </p></td><td></td></tr><tr><td><a href="bnf_int937-artemether-with-lumefantrine.htm">Artemether with Lumefantrine</a></td><td class="cAI"><p><span>possible increased risk of ventricular arrhythmias when </span> <span>vandetanib</span> <span>given with</span> <span>artemether/lumefantrine</span> <span>—avoid concomitant use</span>  </p></td><td></td></tr><tr><td><a href="bnf_int277-carbamazepine.htm">Carbamazepine</a></td><td><p><span>manufacturer of </span> <span>vandetanib</span> <span>advises avoid concomitant use with</span> <span>carbamazepine</span> <span>(plasma concentration of <span>vandetanib</span> possibly reduced)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int374-chlorpromazine.htm">Chlorpromazine</a></td><td class="cAI"><p><span>possible increased risk of ventricular arrhythmias when </span> <span>vandetanib</span> <span>given with</span> <span>chlorpromazine</span> <span>—avoid concomitant use</span>  </p></td><td></td></tr><tr><td><a href="bnf_int119-disopyramide.htm">Disopyramide</a></td><td class="cAI"><p><span>possible increased risk of ventricular arrhythmias when </span> <span>vandetanib</span> <span>given with</span> <span>disopyramide</span> <span>—avoid concomitant use</span>  </p></td><td></td></tr><tr><td><a href="bnf_int169-erythromycin.htm">Erythromycin</a></td><td class="cAI"><p><span>possible increased risk of ventricular arrhythmias when </span> <span>vandetanib</span> <span>given with parenteral</span> <span>erythromycin</span> <span>—avoid concomitant use</span>  </p></td><td><div class="cG"><p><strong>Note:</strong> Interactions do not apply to small amounts of erythromycin used topically</p></div></td></tr><tr><td><a href="bnf_int387-haloperidol.htm">Haloperidol</a></td><td class="cAI"><p><span>possible increased risk of ventricular arrhythmias when </span> <span>vandetanib</span> <span>given with</span> <span>haloperidol</span> <span>—avoid concomitant use</span>  </p></td><td></td></tr><tr><td><a href="bnf_int97-methadone.htm">Methadone</a></td><td class="cAI"><p><span>possible increased risk of ventricular arrhythmias when </span> <span>vandetanib</span> <span>given with</span> <span>methadone</span> <span>—avoid concomitant use</span>  </p></td><td></td></tr><tr><td><a href="bnf_int841-mizolastine.htm">Mizolastine</a></td><td class="cAI"><p><span>possible increased risk of ventricular arrhythmias when </span> <span>vandetanib</span> <span>given with</span> <span>mizolastine</span> <span>—avoid concomitant use</span>  </p></td><td></td></tr><tr><td><a href="bnf_int973-moxifloxacin.htm">Moxifloxacin</a></td><td class="cAI"><p><span>possible increased risk of ventricular arrhythmias when </span> <span>vandetanib</span> <span>given with</span> <span>moxifloxacin</span> <span>—avoid concomitant use</span>  </p></td><td></td></tr><tr><td><a href="bnf_int1045-ondansetron.htm">Ondansetron</a></td><td class="cAI"><p><span>increased risk of ventricular arrhythmias when </span> <span>vandetanib</span> <span>given with</span> <span>ondansetron</span> <span>—avoid concomitant use</span>  </p></td><td></td></tr><tr><td><a href="bnf_int808-pentamidine-isetionate.htm">Pentamidine Isetionate</a></td><td class="cAI"><p><span>possible increased risk of ventricular arrhythmias when </span> <span>vandetanib</span> <span>given with</span> <span>pentamidine isetionate</span> <span>—avoid concomitant use</span>  </p></td><td></td></tr><tr><td><a href="bnf_int437-phenobarbital.htm">Phenobarbital</a></td><td><p><span>manufacturer of </span> <span>vandetanib</span> <span>advises avoid concomitant use with</span> <span>phenobarbital</span> <span>(plasma concentration of <span>vandetanib</span> possibly reduced)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int369-pimozide.htm">Pimozide</a></td><td class="cAI"><p><span>possible increased risk of ventricular arrhythmias when </span> <span>vandetanib</span> <span>given with</span> <span>pimozide</span> <span>—avoid concomitant use</span>  </p></td><td></td></tr><tr><td><a href="bnf_int751-proton-pump-inhibitors.htm">Proton Pump Inhibitors</a></td><td><p><span>manufacturer of </span> <span>vandetanib</span> <span>advises avoid concomitant use with</span> <span>proton pump inhibitors</span> <span>(absorption of <span>vandetanib</span> possibly reduced)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int201-rifampicin.htm">Rifampicin</a></td><td><p><span>manufacturer of </span> <span>vandetanib</span> <span>advises avoid concomitant use with</span> <span>rifampicin</span> <span>(plasma concentration of <span>vandetanib</span> reduced)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int455-sotalol.htm">Sotalol</a></td><td class="cAI"><p><span>possible increased risk of ventricular arrhythmias when </span> <span>vandetanib</span> <span>given with</span> <span>sotalol</span> <span>—avoid concomitant use</span>  </p></td><td></td></tr><tr><td><a href="bnf_int905-st-johns-wort.htm">St John's Wort</a></td><td><p><span>manufacturer of </span> <span>vandetanib</span> <span>advises avoid concomitant use with</span> <span>St John's wort</span> <span>(plasma concentration of <span>vandetanib</span> possibly reduced)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int371-sulpiride.htm">Sulpiride</a></td><td class="cAI"><p><span>possible increased risk of ventricular arrhythmias when </span> <span>vandetanib</span> <span>given with</span> <span>sulpiride</span> <span>—avoid concomitant use</span>  </p></td><td></td></tr><tr><td><a href="bnf_int582-toremifene.htm">Toremifene</a></td><td class="cAI"><p><span>possible increased risk of ventricular arrhythmias when </span> <span>vandetanib</span> <span>given with</span> <span>toremifene</span> <span>—avoid concomitant use</span>  </p></td><td></td></tr><tr><td><a href="bnf_int390-zuclopenthixol.htm">Zuclopenthixol</a></td><td class="cAI"><p><span>possible increased risk of ventricular arrhythmias when </span> <span>vandetanib</span> <span>given with</span> <span>zuclopenthixol</span> <span>—avoid concomitant use</span>  </p></td><td></td></tr></tbody></table><p><strong>Pazopanib</strong> belongs to <strong>Protein Kinase Inhibitors</strong> and has the following interaction information:</p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cAG" /><col width="40%" class="cAF" /><col width="30%" class="cAH" /></colgroup><tbody><tr><td><a href="bnf_int1005-atazanavir.htm">Atazanavir</a></td><td class="cAI"><p><span>manufacturer of </span> <span>pazopanib</span> <span>advises avoid concomitant use with</span> <span>atazanavir</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int1214-boceprevir.htm">Boceprevir</a></td><td class="cAI"><p><span>avoidance of </span> <span>pazopanib</span> <span>advised by manufacturer of</span> <span>boceprevir</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int168-clarithromycin.htm">Clarithromycin</a></td><td class="cAI"><p><span>manufacturer of </span> <span>pazopanib</span> <span>advises avoid concomitant use with</span> <span>clarithromycin</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int829-grapefruit-juice.htm">Grapefruit Juice</a></td><td class="cAI"><p><span>manufacturer of </span> <span>pazopanib</span> <span>advises avoid concomitant use with</span> <span>grapefruit juice</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int398-indinavir.htm">Indinavir</a></td><td class="cAI"><p><span>manufacturer of </span> <span>pazopanib</span> <span>advises avoid concomitant use with</span> <span>indinavir</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int302-itraconazole.htm">Itraconazole</a></td><td class="cAI"><p><span>manufacturer of </span> <span>pazopanib</span> <span>advises avoid concomitant use with</span> <span>itraconazole</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int298-ketoconazole.htm">Ketoconazole</a></td><td class="cAI"><p><span>manufacturer of </span> <span>pazopanib</span> <span>advises avoid concomitant use with</span> <span>ketoconazole</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int1128-lapatinib.htm">Lapatinib</a></td><td><p><span>plasma concentration of </span> <span>pazopanib</span> <span>increased by</span> <span>lapatinib</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int842-nelfinavir.htm">Nelfinavir</a></td><td class="cAI"><p><span>manufacturer of </span> <span>pazopanib</span> <span>advises avoid concomitant use with</span> <span>nelfinavir</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int201-rifampicin.htm">Rifampicin</a></td><td class="cAI"><p><span>manufacturer of </span> <span>pazopanib</span> <span>advises avoid concomitant use with</span> <span>rifampicin</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int400-ritonavir.htm">Ritonavir</a></td><td class="cAI"><p><span>manufacturer of </span> <span>pazopanib</span> <span>advises avoid concomitant use with</span> <span>ritonavir</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int791-saquinavir.htm">Saquinavir</a></td><td class="cAI"><p><span>manufacturer of </span> <span>pazopanib</span> <span>advises avoid concomitant use with</span> <span>saquinavir</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int946-telithromycin.htm">Telithromycin</a></td><td class="cAI"><p><span>manufacturer of </span> <span>pazopanib</span> <span>advises avoid concomitant use with</span> <span>telithromycin</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int948-voriconazole.htm">Voriconazole</a></td><td class="cAI"><p><span>manufacturer of </span> <span>pazopanib</span> <span>advises avoid concomitant use with</span> <span>voriconazole</span> <span></span>  </p></td><td></td></tr></tbody></table><p><strong>Gefitinib</strong> belongs to <strong>Protein Kinase Inhibitors</strong> and has the following interaction information:</p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cAG" /><col width="40%" class="cAF" /><col width="30%" class="cAH" /></colgroup><tbody><tr><td><a href="bnf_int1214-boceprevir.htm">Boceprevir</a></td><td class="cAI"><p><span>avoidance of </span> <span>gefitinib</span> <span>advised by manufacturer of</span> <span>boceprevir</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int277-carbamazepine.htm">Carbamazepine</a></td><td><p><span>manufacturer of </span> <span>gefitinib</span> <span>advises avoid concomitant use with</span> <span>carbamazepine</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int302-itraconazole.htm">Itraconazole</a></td><td><p><span>plasma concentration of </span> <span>gefitinib</span> <span>increased by</span> <span>itraconazole</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int437-phenobarbital.htm">Phenobarbital</a></td><td><p><span>manufacturer of </span> <span>gefitinib</span> <span>advises avoid concomitant use with</span> <span>phenobarbital</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int284-phenytoin.htm">Phenytoin</a></td><td><p><span>manufacturer of </span> <span>gefitinib</span> <span>advises avoid concomitant use with</span> <span>phenytoin</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int747-ranitidine.htm">Ranitidine</a></td><td class="cAI"><p><span>plasma concentration of </span> <span>gefitinib</span> <span>reduced by</span> <span>ranitidine</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int201-rifampicin.htm">Rifampicin</a></td><td class="cAI"><p><span>plasma concentration of </span> <span>gefitinib</span> <span>reduced by</span> <span>rifampicin</span> <span>—avoid concomitant use</span>  </p></td><td></td></tr><tr><td><a href="bnf_int905-st-johns-wort.htm">St John's Wort</a></td><td><p><span>manufacturer of </span> <span>gefitinib</span> <span>advises avoid concomitant use with</span> <span>St John's wort</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int222-warfarin.htm">Warfarin</a></td><td class="cAI"><p><span></span> <span>gefitinib</span> <span>possibly enhances anticoagulant effect of</span> <span>warfarin</span> <span></span>  </p></td><td></td></tr></tbody></table><p><strong>Everolimus</strong> belongs to <strong>Protein Kinase Inhibitors</strong> and has the following interaction information:</p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cAG" /><col width="40%" class="cAF" /><col width="30%" class="cAH" /></colgroup><tbody><tr><td><a href="bnf_int1005-atazanavir.htm">Atazanavir</a></td><td class="cAI"><p><span>plasma concentration of </span> <span>everolimus</span> <span>possibly increased by</span> <span>atazanavir</span> <span>—manufacturer of <span>everolimus</span> advises avoid concomitant use</span>  </p></td><td></td></tr><tr><td><a href="bnf_int499-ciclosporin.htm">Ciclosporin</a></td><td class="cAI"><p><span>plasma concentration of </span> <span>everolimus</span> <span>increased by</span> <span>ciclosporin</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int168-clarithromycin.htm">Clarithromycin</a></td><td class="cAI"><p><span>plasma concentration of </span> <span>everolimus</span> <span>possibly increased by</span> <span>clarithromycin</span> <span>—manufacturer of <span>everolimus</span> advises avoid concomitant use</span>  </p></td><td></td></tr><tr><td><a href="bnf_int1091-darunavir.htm">Darunavir</a></td><td class="cAI"><p><span>plasma concentration of </span> <span>everolimus</span> <span>possibly increased by</span> <span>darunavir</span> <span>—manufacturer of <span>everolimus</span> advises avoid concomitant use</span>  </p></td><td></td></tr><tr><td><a href="bnf_int169-erythromycin.htm">Erythromycin</a></td><td class="cAI"><p><span>plasma concentration of </span> <span>everolimus</span> <span>increased by</span> <span>erythromycin</span> <span></span>  </p></td><td><div class="cG"><p><strong>Note:</strong> Interactions do not apply to small amounts of erythromycin used topically</p></div></td></tr><tr><td><a href="bnf_int829-grapefruit-juice.htm">Grapefruit Juice</a></td><td><p><span>manufacturer of </span> <span>everolimus</span> <span>advises avoid concomitant use with</span> <span>grapefruit juice</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int398-indinavir.htm">Indinavir</a></td><td class="cAI"><p><span>plasma concentration of </span> <span>everolimus</span> <span>possibly increased by</span> <span>indinavir</span> <span>—manufacturer of <span>everolimus</span> advises avoid concomitant use</span>  </p></td><td></td></tr><tr><td><a href="bnf_int302-itraconazole.htm">Itraconazole</a></td><td class="cAI"><p><span>plasma concentration of </span> <span>everolimus</span> <span>possibly increased by</span> <span>itraconazole</span> <span>—manufacturer of <span>everolimus</span> advises avoid concomitant use</span>  </p></td><td></td></tr><tr><td><a href="bnf_int298-ketoconazole.htm">Ketoconazole</a></td><td class="cAI"><p><span>plasma concentration of </span> <span>everolimus</span> <span>increased by</span> <span>ketoconazole</span> <span>—avoid concomitant use</span>  </p></td><td></td></tr><tr><td><a href="bnf_int842-nelfinavir.htm">Nelfinavir</a></td><td class="cAI"><p><span>plasma concentration of </span> <span>everolimus</span> <span>possibly increased by</span> <span>nelfinavir</span> <span>—manufacturer of <span>everolimus</span> advises avoid concomitant use</span>  </p></td><td></td></tr><tr><td><a href="bnf_int1060-posaconazole.htm">Posaconazole</a></td><td class="cAI"><p><span>plasma concentration of </span> <span>everolimus</span> <span>possibly increased by</span> <span>posaconazole</span> <span>—manufacturer of <span>everolimus</span> advises avoid concomitant use</span>  </p></td><td></td></tr><tr><td><a href="bnf_int201-rifampicin.htm">Rifampicin</a></td><td class="cAI"><p><span>plasma concentration of </span> <span>everolimus</span> <span>reduced by</span> <span>rifampicin</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int400-ritonavir.htm">Ritonavir</a></td><td class="cAI"><p><span>plasma concentration of </span> <span>everolimus</span> <span>possibly increased by</span> <span>ritonavir</span> <span>—manufacturer of <span>everolimus</span> advises avoid concomitant use</span>  </p></td><td></td></tr><tr><td><a href="bnf_int791-saquinavir.htm">Saquinavir</a></td><td class="cAI"><p><span>plasma concentration of </span> <span>everolimus</span> <span>possibly increased by</span> <span>saquinavir</span> <span>—manufacturer of <span>everolimus</span> advises avoid concomitant use</span>  </p></td><td></td></tr><tr><td><a href="bnf_int905-st-johns-wort.htm">St John's Wort</a></td><td><p><span>plasma concentration of </span> <span>everolimus</span> <span>possibly reduced by</span> <span>St John's wort</span> <span>—manufacturer of <span>everolimus</span> advises avoid concomitant use</span>  </p></td><td></td></tr><tr><td><a href="bnf_int946-telithromycin.htm">Telithromycin</a></td><td class="cAI"><p><span>plasma concentration of </span> <span>everolimus</span> <span>possibly increased by</span> <span>telithromycin</span> <span>—manufacturer of <span>everolimus</span> advises avoid concomitant use</span>  </p></td><td></td></tr><tr><td><a href="bnf_int467-verapamil.htm">Verapamil</a></td><td class="cAI"><p><span>plasma concentration of both drugs may increase when </span> <span>everolimus</span> <span>given with</span> <span>verapamil</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int948-voriconazole.htm">Voriconazole</a></td><td class="cAI"><p><span>plasma concentration of </span> <span>everolimus</span> <span>possibly increased by</span> <span>voriconazole</span> <span>—manufacturer of <span>everolimus</span> advises avoid concomitant use</span>  </p></td><td></td></tr></tbody></table><p><strong>Temsirolimus</strong> belongs to <strong>Protein Kinase Inhibitors</strong> and has the following interaction information:</p><div class="cG"><p><strong>Note:</strong> The main active metabolite of temsirolimus is sirolimus—see also interactions of sirolimus and consult product literature</p></div><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cAG" /><col width="40%" class="cAF" /><col width="30%" class="cAH" /></colgroup><tbody><tr><td><a href="bnf_int298-ketoconazole.htm">Ketoconazole</a></td><td class="cAI"><p><span>plasma concentration of active metabolite of </span> <span>temsirolimus</span> <span>increased by</span> <span>ketoconazole</span> <span>—avoid concomitant use</span>  </p></td><td></td></tr><tr><td><a href="bnf_int201-rifampicin.htm">Rifampicin</a></td><td class="cAI"><p><span>plasma concentration of active metabolite of </span> <span>temsirolimus</span> <span>reduced by</span> <span>rifampicin</span> <span>—avoid concomitant use</span>  </p></td><td></td></tr></tbody></table><p><strong>Lapatinib</strong> belongs to <strong>Protein Kinase Inhibitors</strong> and has the following interaction information:</p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cAG" /><col width="40%" class="cAF" /><col width="30%" class="cAH" /></colgroup><tbody><tr><td><a href="bnf_int1214-boceprevir.htm">Boceprevir</a></td><td class="cAI"><p><span>avoidance of </span> <span>lapatinib</span> <span>advised by manufacturer of</span> <span>boceprevir</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int277-carbamazepine.htm">Carbamazepine</a></td><td class="cAI"><p><span>plasma concentration of </span> <span>lapatinib</span> <span>reduced by</span> <span>carbamazepine</span> <span>—avoid concomitant use</span>  </p></td><td></td></tr><tr><td><a href="bnf_int516-docetaxel.htm">Docetaxel</a></td><td><p><span>possible increased risk of neutropenia when </span> <span>lapatinib</span> <span>given with</span> <span>docetaxel</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int829-grapefruit-juice.htm">Grapefruit Juice</a></td><td class="cAI"><p><span>manufacturer of </span> <span>lapatinib</span> <span>advises avoid concomitant use with</span> <span>grapefruit juice</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int743-histamine-h-2-antagonists.htm">Histamine H<sub>2</sub>-antagonists</a></td><td><p><span>absorption of </span> <span>lapatinib</span> <span>possibly reduced by</span> <span>histamine H<sub>2</sub>-antagonists</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int1006-irinotecan.htm">Irinotecan</a></td><td class="cAI"><p><span></span> <span>lapatinib</span> <span>increases plasma concentration of active metabolite of</span> <span>irinotecan</span> <span>—consider reducing dose of <span>irinotecan</span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int302-itraconazole.htm">Itraconazole</a></td><td class="cAI"><p><span>manufacturer of </span> <span>lapatinib</span> <span>advises avoid concomitant use with</span> <span>itraconazole</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int298-ketoconazole.htm">Ketoconazole</a></td><td class="cAI"><p><span>plasma concentration of </span> <span>lapatinib</span> <span>increased by</span> <span>ketoconazole</span> <span>—avoid concomitant use</span>  </p></td><td></td></tr><tr><td><a href="bnf_int517-paclitaxel.htm">Paclitaxel</a></td><td class="cAI"><p><span>increased risk of neutropenia when </span> <span>lapatinib</span> <span>given with</span> <span>paclitaxel</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int1186-pazopanib.htm">Pazopanib</a></td><td><p><span></span> <span>lapatinib</span> <span>increases plasma concentration of</span> <span>pazopanib</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int284-phenytoin.htm">Phenytoin</a></td><td class="cAI"><p><span>manufacturer of </span> <span>lapatinib</span> <span>advises avoid concomitant use with</span> <span>phenytoin</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int369-pimozide.htm">Pimozide</a></td><td class="cAI"><p><span>manufacturer of </span> <span>lapatinib</span> <span>advises avoid concomitant use with</span> <span>pimozide</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int1060-posaconazole.htm">Posaconazole</a></td><td class="cAI"><p><span>manufacturer of </span> <span>lapatinib</span> <span>advises avoid concomitant use with</span> <span>posaconazole</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int751-proton-pump-inhibitors.htm">Proton Pump Inhibitors</a></td><td><p><span>absorption of </span> <span>lapatinib</span> <span>possibly reduced by</span> <span>proton pump inhibitors</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int855-repaglinide.htm">Repaglinide</a></td><td class="cAI"><p><span>manufacturer of </span> <span>lapatinib</span> <span>advises avoid concomitant use with</span> <span>repaglinide</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int200-rifabutin.htm">Rifabutin</a></td><td class="cAI"><p><span>manufacturer of </span> <span>lapatinib</span> <span>advises avoid concomitant use with</span> <span>rifabutin</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int201-rifampicin.htm">Rifampicin</a></td><td class="cAI"><p><span>manufacturer of </span> <span>lapatinib</span> <span>advises avoid concomitant use with</span> <span>rifampicin</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int400-ritonavir.htm">Ritonavir</a></td><td class="cAI"><p><span>manufacturer of </span> <span>lapatinib</span> <span>advises avoid concomitant use with</span> <span>ritonavir</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int791-saquinavir.htm">Saquinavir</a></td><td class="cAI"><p><span>manufacturer of </span> <span>lapatinib</span> <span>advises avoid concomitant use with</span> <span>saquinavir</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int905-st-johns-wort.htm">St John's Wort</a></td><td class="cAI"><p><span>manufacturer of </span> <span>lapatinib</span> <span>advises avoid concomitant use with</span> <span>St John's wort</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int946-telithromycin.htm">Telithromycin</a></td><td class="cAI"><p><span>manufacturer of </span> <span>lapatinib</span> <span>advises avoid concomitant use with</span> <span>telithromycin</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int948-voriconazole.htm">Voriconazole</a></td><td class="cAI"><p><span>manufacturer of </span> <span>lapatinib</span> <span>advises avoid concomitant use with</span> <span>voriconazole</span> <span></span>  </p></td><td></td></tr></tbody></table><p><strong>Nilotinib</strong> belongs to <strong>Protein Kinase Inhibitors</strong> and has the following interaction information:</p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cAG" /><col width="40%" class="cAF" /><col width="30%" class="cAH" /></colgroup><tbody><tr><td><a href="bnf_int1214-boceprevir.htm">Boceprevir</a></td><td class="cAI"><p><span>avoidance of </span> <span>nilotinib</span> <span>advised by manufacturer of</span> <span>boceprevir</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int168-clarithromycin.htm">Clarithromycin</a></td><td class="cAI"><p><span>manufacturer of </span> <span>nilotinib</span> <span>advises avoid concomitant use with</span> <span>clarithromycin</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int829-grapefruit-juice.htm">Grapefruit Juice</a></td><td class="cAI"><p><span>manufacturer of </span> <span>nilotinib</span> <span>advises avoid concomitant use with</span> <span>grapefruit juice</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int302-itraconazole.htm">Itraconazole</a></td><td class="cAI"><p><span>manufacturer of </span> <span>nilotinib</span> <span>advises avoid concomitant use with</span> <span>itraconazole</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int298-ketoconazole.htm">Ketoconazole</a></td><td class="cAI"><p><span>plasma concentration of </span> <span>nilotinib</span> <span>increased by</span> <span>ketoconazole</span> <span>—avoid concomitant use</span>  </p></td><td></td></tr><tr><td><a href="bnf_int421-midazolam.htm">Midazolam</a></td><td><p><span></span> <span>nilotinib</span> <span>increases plasma concentration of</span> <span>midazolam</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int201-rifampicin.htm">Rifampicin</a></td><td class="cAI"><p><span>plasma concentration of </span> <span>nilotinib</span> <span>reduced by</span> <span>rifampicin</span> <span>—avoid concomitant use</span>  </p></td><td></td></tr><tr><td><a href="bnf_int400-ritonavir.htm">Ritonavir</a></td><td><p><span>plasma concentration of </span> <span>nilotinib</span> <span>possibly increased by</span> <span>ritonavir</span> <span>—manufacturer of <span>nilotinib</span> advises avoid concomitant use</span>  </p></td><td></td></tr><tr><td><a href="bnf_int946-telithromycin.htm">Telithromycin</a></td><td class="cAI"><p><span>manufacturer of </span> <span>nilotinib</span> <span>advises avoid concomitant use with</span> <span>telithromycin</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int948-voriconazole.htm">Voriconazole</a></td><td class="cAI"><p><span>manufacturer of </span> <span>nilotinib</span> <span>advises avoid concomitant use with</span> <span>voriconazole</span> <span></span>  </p></td><td></td></tr></tbody></table><p><strong>Sunitinib</strong> belongs to <strong>Protein Kinase Inhibitors</strong> and has the following interaction information:</p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cAG" /><col width="40%" class="cAF" /><col width="30%" class="cAH" /></colgroup><tbody><tr><td><a href="bnf_int1214-boceprevir.htm">Boceprevir</a></td><td class="cAI"><p><span>avoidance of </span> <span>sunitinib</span> <span>advised by manufacturer of</span> <span>boceprevir</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int298-ketoconazole.htm">Ketoconazole</a></td><td><p><span>metabolism of </span> <span>sunitinib</span> <span>inhibited by</span> <span>ketoconazole</span> <span>(increased plasma concentration)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int201-rifampicin.htm">Rifampicin</a></td><td><p><span>metabolism of </span> <span>sunitinib</span> <span>accelerated by</span> <span>rifampicin</span> <span>(reduced plasma concentration)</span>  </p></td><td></td></tr></tbody></table><p><strong>Sorafenib</strong> belongs to <strong>Protein Kinase Inhibitors</strong> and has the following interaction information:</p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cAG" /><col width="40%" class="cAF" /><col width="30%" class="cAH" /></colgroup><tbody><tr><td><a href="bnf_int1214-boceprevir.htm">Boceprevir</a></td><td class="cAI"><p><span>avoidance of </span> <span>sorafenib</span> <span>advised by manufacturer of</span> <span>boceprevir</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int220-coumarins.htm">Coumarins</a></td><td class="cAI"><p><span></span> <span>sorafenib</span> <span>possibly enhances anticoagulant effect of</span> <span>coumarins</span> <span></span>  </p></td><td><div class="cG"><p><strong>Note:</strong> Change in patient's clinical condition, particularly associated with liver disease, intercurrent illness, or drug administration, necessitates more frequent testing. Major changes in diet (especially involving salads and vegetables) and in alcohol consumption may also affect anticoagulant control</p></div></td></tr><tr><td><a href="bnf_int516-docetaxel.htm">Docetaxel</a></td><td><p><span></span> <span>sorafenib</span> <span>increases plasma concentration of</span> <span>docetaxel</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int506-doxorubicin.htm">Doxorubicin</a></td><td><p><span></span> <span>sorafenib</span> <span>possibly increases plasma concentration of</span> <span>doxorubicin</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int1006-irinotecan.htm">Irinotecan</a></td><td><p><span></span> <span>sorafenib</span> <span>possibly increases plasma concentration of</span> <span>irinotecan</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int133-neomycin.htm">Neomycin</a></td><td><p><span>bioavailability of </span> <span>sorafenib</span> <span>reduced by</span> <span>neomycin</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int201-rifampicin.htm">Rifampicin</a></td><td><p><span>plasma concentration of </span> <span>sorafenib</span> <span>reduced by</span> <span>rifampicin</span> <span></span>  </p></td><td></td></tr></tbody></table><p><strong>Imatinib</strong> belongs to <strong>Protein Kinase Inhibitors</strong> and has the following interaction information:</p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cAG" /><col width="40%" class="cAF" /><col width="30%" class="cAH" /></colgroup><tbody><tr><td><a href="bnf_int1214-boceprevir.htm">Boceprevir</a></td><td class="cAI"><p><span>avoidance of </span> <span>imatinib</span> <span>advised by manufacturer of</span> <span>boceprevir</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int277-carbamazepine.htm">Carbamazepine</a></td><td class="cAI"><p><span>plasma concentration of </span> <span>imatinib</span> <span>reduced by</span> <span>carbamazepine</span> <span>—avoid concomitant use</span>  </p></td><td></td></tr><tr><td><a href="bnf_int499-ciclosporin.htm">Ciclosporin</a></td><td><p><span></span> <span>imatinib</span> <span>possibly increases plasma concentration of</span> <span>ciclosporin</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int298-ketoconazole.htm">Ketoconazole</a></td><td><p><span>plasma concentration of </span> <span>imatinib</span> <span>increased by</span> <span>ketoconazole</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int738-levothyroxine.htm">Levothyroxine</a></td><td><p><span></span> <span>imatinib</span> <span>possibly reduces plasma concentration of</span> <span>levothyroxine</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int900-oxcarbazepine.htm">Oxcarbazepine</a></td><td class="cAI"><p><span>plasma concentration of </span> <span>imatinib</span> <span>reduced by</span> <span>oxcarbazepine</span> <span>—avoid concomitant use</span>  </p></td><td></td></tr><tr><td><a href="bnf_int59-paracetamol.htm">Paracetamol</a></td><td><p><span>manufacturer of </span> <span>imatinib</span> <span>advises caution with</span> <span>paracetamol</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int284-phenytoin.htm">Phenytoin</a></td><td class="cAI"><p><span>plasma concentration of </span> <span>imatinib</span> <span>reduced by</span> <span>phenytoin</span> <span>—avoid concomitant use</span>  </p></td><td></td></tr><tr><td><a href="bnf_int201-rifampicin.htm">Rifampicin</a></td><td class="cAI"><p><span>plasma concentration of </span> <span>imatinib</span> <span>reduced by</span> <span>rifampicin</span> <span>—avoid concomitant use</span>  </p></td><td></td></tr><tr><td><a href="bnf_int605-simvastatin.htm">Simvastatin</a></td><td><p><span></span> <span>imatinib</span> <span>increases plasma concentration of</span> <span>simvastatin</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int905-st-johns-wort.htm">St John's Wort</a></td><td class="cAI"><p><span>plasma concentration of </span> <span>imatinib</span> <span>reduced by</span> <span>St John's wort</span> <span>—avoid concomitant use</span>  </p></td><td></td></tr><tr><td><a href="bnf_int222-warfarin.htm">Warfarin</a></td><td><p><span>manufacturer of </span> <span>imatinib</span> <span>advises replacement of</span> <span>warfarin</span> <span>with a heparin (possibility of enhanced <span>warfarin</span> effect)</span>  </p></td><td></td></tr></tbody></table><p><strong>Erlotinib</strong> belongs to <strong>Protein Kinase Inhibitors</strong> and has the following interaction information:</p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cAG" /><col width="40%" class="cAF" /><col width="30%" class="cAH" /></colgroup><tbody><tr><td><a href="bnf_int110-antacids.htm">Antacids</a></td><td class="cAI"><p><span>plasma concentration of </span> <span>erlotinib</span> <span>possibly reduced by</span> <span>antacids</span> <span>—give <span>antacids</span> at least 4 hours before or 2 hours after <span>erlotinib</span></span>  </p></td><td><div class="cG"><p><strong>Note:</strong> Antacids should preferably not be taken at the same time as other drugs since they may impair absorption</p></div></td></tr><tr><td><a href="bnf_int1214-boceprevir.htm">Boceprevir</a></td><td class="cAI"><p><span>avoidance of </span> <span>erlotinib</span> <span>advised by manufacturer of</span> <span>boceprevir</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int923-capecitabine.htm">Capecitabine</a></td><td><p><span>plasma concentration of </span> <span>erlotinib</span> <span>possibly increased by</span> <span>capecitabine</span> <span></span>  </p></td><td><div class="cG"><p><strong>Note:</strong> Capecitabine is a prodrug of fluorouracil</p></div></td></tr><tr><td><a href="bnf_int744-cimetidine.htm">Cimetidine</a></td><td class="cAI"><p><span>manufacturer of </span> <span>erlotinib</span> <span>advises avoid concomitant use with</span> <span>cimetidine</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int195-ciprofloxacin.htm">Ciprofloxacin</a></td><td><p><span>plasma concentration of </span> <span>erlotinib</span> <span>increased by</span> <span>ciprofloxacin</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int220-coumarins.htm">Coumarins</a></td><td class="cAI"><p><span>increased risk of bleeding when </span> <span>erlotinib</span> <span>given with</span> <span>coumarins</span> <span></span>  </p></td><td><div class="cG"><p><strong>Note:</strong> Change in patient's clinical condition, particularly associated with liver disease, intercurrent illness, or drug administration, necessitates more frequent testing. Major changes in diet (especially involving salads and vegetables) and in alcohol consumption may also affect anticoagulant control</p></div></td></tr><tr><td><a href="bnf_int914-esomeprazole.htm">Esomeprazole</a></td><td class="cAI"><p><span>manufacturer of </span> <span>erlotinib</span> <span>advises avoid concomitant use with</span> <span>esomeprazole</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int745-famotidine.htm">Famotidine</a></td><td class="cAI"><p><span>manufacturer of </span> <span>erlotinib</span> <span>advises avoid concomitant use with</span> <span>famotidine</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int298-ketoconazole.htm">Ketoconazole</a></td><td><p><span>metabolism of </span> <span>erlotinib</span> <span>inhibited by</span> <span>ketoconazole</span> <span>(increased plasma concentration)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int753-lansoprazole.htm">Lansoprazole</a></td><td class="cAI"><p><span>manufacturer of </span> <span>erlotinib</span> <span>advises avoid concomitant use with</span> <span>lansoprazole</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int60-nsaids.htm">NSAIDs</a></td><td class="cAI"><p><span>increased risk of bleeding when </span> <span>erlotinib</span> <span>given with</span> <span>NSAIDs</span> <span></span>  </p></td><td><div class="cG"><p><strong>Note:</strong> See also Aspirin. Interactions do not generally apply to topical NSAIDs
</p></div></td></tr><tr><td><a href="bnf_int746-nizatidine.htm">Nizatidine</a></td><td class="cAI"><p><span>manufacturer of </span> <span>erlotinib</span> <span>advises avoid concomitant use with</span> <span>nizatidine</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int752-omeprazole.htm">Omeprazole</a></td><td class="cAI"><p><span>plasma concentration of </span> <span>erlotinib</span> <span>reduced by</span> <span>omeprazole</span> <span>—manufacturer of <span>erlotinib</span> advises avoid concomitant use</span>  </p></td><td></td></tr><tr><td><a href="bnf_int754-pantoprazole.htm">Pantoprazole</a></td><td class="cAI"><p><span>manufacturer of </span> <span>erlotinib</span> <span>advises avoid concomitant use with</span> <span>pantoprazole</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int869-rabeprazole.htm">Rabeprazole</a></td><td class="cAI"><p><span>manufacturer of </span> <span>erlotinib</span> <span>advises avoid concomitant use with</span> <span>rabeprazole</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int747-ranitidine.htm">Ranitidine</a></td><td class="cAI"><p><span>plasma concentration of </span> <span>erlotinib</span> <span>reduced by</span> <span>ranitidine</span> <span>—manufacturer of <span>erlotinib</span> advises give at least 2 hours before or 10 hours after <span>ranitidine</span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int201-rifampicin.htm">Rifampicin</a></td><td><p><span>metabolism of </span> <span>erlotinib</span> <span>accelerated by</span> <span>rifampicin</span> <span>(reduced plasma concentration)</span>  </p></td><td></td></tr></tbody></table><p><strong>Dasatinib</strong> belongs to <strong>Protein Kinase Inhibitors</strong> and has the following interaction information:</p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cAG" /><col width="40%" class="cAF" /><col width="30%" class="cAH" /></colgroup><tbody><tr><td><a href="bnf_int1214-boceprevir.htm">Boceprevir</a></td><td class="cAI"><p><span>avoidance of </span> <span>dasatinib</span> <span>advised by manufacturer of</span> <span>boceprevir</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int745-famotidine.htm">Famotidine</a></td><td><p><span>plasma concentration of </span> <span>dasatinib</span> <span>possibly reduced by</span> <span>famotidine</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int298-ketoconazole.htm">Ketoconazole</a></td><td><p><span>plasma concentration of </span> <span>dasatinib</span> <span>possibly increased by</span> <span>ketoconazole</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int201-rifampicin.htm">Rifampicin</a></td><td class="cAI"><p><span>metabolism of </span> <span>dasatinib</span> <span>accelerated by</span> <span>rifampicin</span> <span>(reduced plasma concentration—avoid concomitant use)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int605-simvastatin.htm">Simvastatin</a></td><td><p><span></span> <span>dasatinib</span> <span>possibly increases plasma concentration of</span> <span>simvastatin</span> <span></span>  </p></td><td></td></tr></tbody></table></div><div id="pS"><p>Sub-sections</p><ul class="jT"><li><a href="bnf_int1229-vemurafenib.htm" title="Vemurafenib">Vemurafenib</a></li><li><a href="bnf_int1227-vandetanib.htm" title="Vandetanib">Vandetanib</a></li><li><a href="bnf_int1186-pazopanib.htm" title="Pazopanib">Pazopanib</a></li><li><a href="bnf_int1170-gefitinib.htm" title="Gefitinib">Gefitinib</a></li><li><a href="bnf_int1169-everolimus.htm" title="Everolimus">Everolimus</a></li><li><a href="bnf_int1137-temsirolimus.htm" title="Temsirolimus">Temsirolimus</a></li><li><a href="bnf_int1128-lapatinib.htm" title="Lapatinib">Lapatinib</a></li><li><a href="bnf_int1118-nilotinib.htm" title="Nilotinib">Nilotinib</a></li><li><a href="bnf_int1075-sunitinib.htm" title="Sunitinib">Sunitinib</a></li><li><a href="bnf_int1074-sorafenib.htm" title="Sorafenib">Sorafenib</a></li><li><a href="bnf_int933-imatinib.htm" title="Imatinib">Imatinib</a></li><li><a href="bnf_int1048-erlotinib.htm" title="Erlotinib">Erlotinib</a></li><li><a href="bnf_int1077-dasatinib.htm" title="Dasatinib">Dasatinib</a></li></ul></div><?highlighter off?><div id="pE">◄ <a accesskey="[" href="bnf_int1103-trabectedin.htm">Previous: Trabectedin</a> | <a class="top" href="bnf_int1087-protein-kinase-inhibitors.htm#">Top</a> | <a accesskey="]" href="bnf_int1229-vemurafenib.htm">Next: Vemurafenib</a> ►</div></div></div><div id="pF"><div id="pL"><div id="footer"><div id="footerinner"><ul><li><a accesskey="0" href="accessibility.htm" title="Accessibility information: access key 0">Accessibility</a> | </li><li><a href="http://www.medicinescomplete.com/mc/marketing/current/contact.htm">Contact Us</a> | </li><li><a href="privacy.htm" title="Cookie and Privacy Policy">Cookie and Privacy Policy</a> | </li><li><a accesskey="3" href="http://www.medicinescomplete.com/mc/sitemap.htm" title="Site Map: access key 3">Site Map</a> | </li><li><a accesskey="8" href="terms.htm" title="Terms and Conditions: access key 8">Terms and Conditions</a></li></ul></div></div></div><div id="pX"><p><a href="PHP0-publication-information.htm" rel="copyright">Copyright © BMJ Group and Pharmaceutical Press 2012. All rights reserved. </a></p></div></div><script type="text/javascript">$(document).ready(function(){$.ga('UA-9959526-1');});</script></body></html>